SEARCH

SEARCH BY CITATION

References

  • 1
    Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13:12665709.
  • 2
    Page EK, Dar WA, Knechtle S. Tolerogenic therapies in transplantation. Front Immunol 2012;3:198.
  • 3
    Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28:58596.
  • 4
    Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010;1:2.
  • 5
    English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 +  regulatory T cells. Clin Exp Immunol 2009;156:14960.
  • 6
    Duffy MM, Ritter T, Ceredig R, Griffin M. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011;2:34.
  • 7
    Sajic M, Hunt DP, Lee W et al. Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation. PLoS ONE 2012;7:e30708.
  • 8
    Al Jumah MA, Abumaree MH. The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). Int J Mol Sci 2012;13:9298331.
  • 9
    Bai L, Lennon DP, Eaton V et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009;57:1192203.
  • 10
    Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007;61:21927.
  • 11
    Kassis I, Grigoriadis N, Gowda-Kurkalli B et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008;65:75361.
  • 12
    Morando S, Vigo T, Esposito M et al. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 2012;3:3.
  • 13
    Darlington P, Boivin M-N, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011;11:1295303.
  • 14
    Chen P-M, Yen M-L, Liu K-Oб, Sytwu H-K, Yen B-L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci 2011;18:49.
  • 15
    Rubtsov YP, Suzdaltseva YG, Goryunov KV, Kalinina NI, Sysoeva VY, Tkachuk VA. Regulation of immunity via multipotent mesenchymal stromal cells. Acta Naturae 2012;4:2331.
  • 16
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:181522.
  • 17
    Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:11023.
  • 18
    Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:1437.
  • 19
    Zafranskaya MM, Nizheharodava DB, Yurkevich MY et al. In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. Immunol Lett 2013;149:918.
  • 20
    Bifari F, Pacelli L, Krampera M. Immunological properties of embryonic and adult stem cells. World J Stem Cells 2010;2:5060.
  • 21
    Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:383843.
  • 22
    Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:37229.
  • 23
    Zafranskaya M, Oschmann P, Engel R et al. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology 2007;121:2939.
  • 24
    Kang JW, Kang K-S, Koo HC, Park JR, Choi EW, Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 2008;17:68194.
  • 25
    Solchaga LA, Zale EA. Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells 2012;1:13845.
  • 26
    Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19:66779.
  • 27
    Lord AM, North TE, Zon LI. Prostaglandin E2. Cell Cycle 2007;6:30547.
  • 28
    Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 2010;316:310923.
  • 29
    Tilley SL, Coffman TM, Koller BH. Mixed message: modulation of inflammation and immune responses by prostaglandins and thromboxane. J Clin Invest 2001;108:159.
  • 30
    Ren G, Su J, Zhang L et al. Species variation in the mechanisms of mesenchymal stem cell–mediated immunosuppression. Stem Cells 2009;27:195462.
  • 31
    Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:38698.